NSG 552 EXAMS 1–3 WU PSYCHOPHARMACOLOGY –
(2026/2027) ACTUAL QUESTIONS, VERIFIED ANSWERS
WITH RATIONALES | GUARANTEE PASS
NSG 552 PSYCHOPHARMACOLOGY — EXAMS 1–3
COMPREHENSIVE 200-QUESTION PRACTICE EXAMINATION
Table of Contents
Module / Topic Questions Distribution
1. Psychopharmacology Foundations & Pharmacokinetics 1–20 20
2. Neurotransmitters, Receptors & Neurobiology 21–40 20
3. Antidepressant Medications 41–70 30
4. Antipsychotic Medications 71–100 30
5. Mood Stabilizers & Bipolar Disorder 101–125 25
6. Anxiolytics, Sedative-Hypnotics & Related Agents 126–150 25
7. ADHD, Substance Use & Other Neuropsychiatric Pharmacology 151–170 20
8. Special Populations, Safety, Monitoring & Clinical Integration 171–200 30
Total 200 200 questions
Module 1 — Psychopharmacology Foundations & Pharmacokinetics
Question 1
A patient begins an oral psychotropic medication that undergoes extensive hepatic metabolism
before reaching systemic circulation. Which pharmacokinetic process most directly accounts for
reduced systemic availability?
A. Renal clearance
B. First-pass metabolism
C. Protein binding
D. Glomerular filtration
,Correct Answer: B
Rationale: First-pass metabolism occurs when an orally administered drug is metabolized in the
gastrointestinal tract and/or liver before reaching systemic circulation, reducing bioavailability.
Renal clearance and glomerular filtration primarily affect elimination, while protein binding
affects distribution and the free fraction of medication.
Question 2
A medication has a half-life of approximately 24 hours. Approximately how long would
generally be required to reach near steady-state concentrations after repeated dosing?
A. 24 hours
B. 48 hours
C. 4–5 days
D. 10–14 days
Correct Answer: C
Rationale: Most drugs approach steady state after approximately four to five half-lives. A 24-
hour half-life therefore corresponds to roughly four to five days, although the precise time
depends on the drug's pharmacokinetic characteristics.
Question 3
A patient with severe hepatic impairment is prescribed a medication extensively metabolized by
the liver. Which pharmacokinetic consequence is most likely?
A. Increased drug clearance
B. Reduced elimination half-life
C. Increased risk of drug accumulation
D. Complete prevention of drug absorption
Correct Answer: C
Rationale: Impaired hepatic metabolism can decrease clearance and prolong the medication's
half-life, increasing the risk of accumulation. Hepatic impairment does not necessarily prevent
absorption but can substantially alter subsequent metabolism and exposure.
Question 4
Which statement best describes a medication's therapeutic index?
A. The percentage of medication absorbed from the gastrointestinal tract
B. The relationship between toxic and therapeutic doses
C. The rate at which a medication reaches the brain
D. The percentage of medication eliminated unchanged in urine
,Correct Answer: B
Rationale: The therapeutic index describes the relative separation between effective and toxic
doses and is useful in evaluating medication safety. A narrow therapeutic index means relatively
small changes in concentration can result in toxicity or loss of efficacy.
Question 5
A medication is highly protein bound. Which clinical situation could increase the concentration
of its pharmacologically active free fraction?
A. Increased plasma albumin
B. Hypoalbuminemia
C. Increased renal filtration
D. Reduced gastrointestinal motility
Correct Answer: B
Rationale: Low albumin can reduce protein binding and increase the free fraction of highly
protein-bound drugs. The unbound fraction is generally more available for pharmacologic
activity and elimination.
Question 6
A patient asks why a medication with a short half-life may need to be administered several times
per day. Which response is most appropriate?
A. Short half-life generally produces faster elimination
B. Short half-life guarantees greater efficacy
C. Short half-life prevents hepatic metabolism
D. Short half-life eliminates the possibility of adverse effects
Correct Answer: A
Rationale: Drugs with short half-lives are eliminated relatively rapidly and may require more
frequent dosing to maintain therapeutic concentrations. Half-life does not by itself determine
efficacy or eliminate adverse effects.
Question 7
A patient experiences adverse effects shortly after beginning a psychotropic medication, despite
receiving the recommended dose. Which pharmacokinetic factor can contribute to unusually high
exposure?
A. Genetic variation in drug-metabolizing enzymes
B. Therapeutic adherence
, C. Placebo response
D. Receptor downregulation alone
Correct Answer: A
Rationale: Pharmacogenetic differences can cause some individuals to metabolize medications
more slowly or rapidly than expected, altering exposure. Placebo response and receptor
regulation involve pharmacodynamic rather than primary pharmacokinetic mechanisms.
Question 8
Which term describes the process by which a medication produces its biologic effect after
binding to a receptor?
A. Pharmacokinetics
B. Pharmacodynamics
C. Bioavailability
D. Clearance
Correct Answer: B
Rationale: Pharmacodynamics concerns what a drug does to the body, including receptor
interactions and downstream physiologic effects. Pharmacokinetics describes what the body does
to the drug through absorption, distribution, metabolism, and elimination.
Question 9
A patient stops taking a medication abruptly after long-term use and develops symptoms
associated with physiologic adaptation. Which concept best explains this phenomenon?
A. Drug tolerance
B. Physical dependence
C. Therapeutic index
D. First-pass metabolism
Correct Answer: B
Rationale: Physical dependence occurs when neuroadaptation produces withdrawal symptoms
after dose reduction or discontinuation. Tolerance refers to reduced response requiring increased
exposure, whereas first-pass metabolism concerns oral drug disposition.
Question 10
A patient reports that the same dose of a medication has become progressively less effective over
several months. Which phenomenon is most consistent with this report?
A. Tolerance
B. Bioavailability
(2026/2027) ACTUAL QUESTIONS, VERIFIED ANSWERS
WITH RATIONALES | GUARANTEE PASS
NSG 552 PSYCHOPHARMACOLOGY — EXAMS 1–3
COMPREHENSIVE 200-QUESTION PRACTICE EXAMINATION
Table of Contents
Module / Topic Questions Distribution
1. Psychopharmacology Foundations & Pharmacokinetics 1–20 20
2. Neurotransmitters, Receptors & Neurobiology 21–40 20
3. Antidepressant Medications 41–70 30
4. Antipsychotic Medications 71–100 30
5. Mood Stabilizers & Bipolar Disorder 101–125 25
6. Anxiolytics, Sedative-Hypnotics & Related Agents 126–150 25
7. ADHD, Substance Use & Other Neuropsychiatric Pharmacology 151–170 20
8. Special Populations, Safety, Monitoring & Clinical Integration 171–200 30
Total 200 200 questions
Module 1 — Psychopharmacology Foundations & Pharmacokinetics
Question 1
A patient begins an oral psychotropic medication that undergoes extensive hepatic metabolism
before reaching systemic circulation. Which pharmacokinetic process most directly accounts for
reduced systemic availability?
A. Renal clearance
B. First-pass metabolism
C. Protein binding
D. Glomerular filtration
,Correct Answer: B
Rationale: First-pass metabolism occurs when an orally administered drug is metabolized in the
gastrointestinal tract and/or liver before reaching systemic circulation, reducing bioavailability.
Renal clearance and glomerular filtration primarily affect elimination, while protein binding
affects distribution and the free fraction of medication.
Question 2
A medication has a half-life of approximately 24 hours. Approximately how long would
generally be required to reach near steady-state concentrations after repeated dosing?
A. 24 hours
B. 48 hours
C. 4–5 days
D. 10–14 days
Correct Answer: C
Rationale: Most drugs approach steady state after approximately four to five half-lives. A 24-
hour half-life therefore corresponds to roughly four to five days, although the precise time
depends on the drug's pharmacokinetic characteristics.
Question 3
A patient with severe hepatic impairment is prescribed a medication extensively metabolized by
the liver. Which pharmacokinetic consequence is most likely?
A. Increased drug clearance
B. Reduced elimination half-life
C. Increased risk of drug accumulation
D. Complete prevention of drug absorption
Correct Answer: C
Rationale: Impaired hepatic metabolism can decrease clearance and prolong the medication's
half-life, increasing the risk of accumulation. Hepatic impairment does not necessarily prevent
absorption but can substantially alter subsequent metabolism and exposure.
Question 4
Which statement best describes a medication's therapeutic index?
A. The percentage of medication absorbed from the gastrointestinal tract
B. The relationship between toxic and therapeutic doses
C. The rate at which a medication reaches the brain
D. The percentage of medication eliminated unchanged in urine
,Correct Answer: B
Rationale: The therapeutic index describes the relative separation between effective and toxic
doses and is useful in evaluating medication safety. A narrow therapeutic index means relatively
small changes in concentration can result in toxicity or loss of efficacy.
Question 5
A medication is highly protein bound. Which clinical situation could increase the concentration
of its pharmacologically active free fraction?
A. Increased plasma albumin
B. Hypoalbuminemia
C. Increased renal filtration
D. Reduced gastrointestinal motility
Correct Answer: B
Rationale: Low albumin can reduce protein binding and increase the free fraction of highly
protein-bound drugs. The unbound fraction is generally more available for pharmacologic
activity and elimination.
Question 6
A patient asks why a medication with a short half-life may need to be administered several times
per day. Which response is most appropriate?
A. Short half-life generally produces faster elimination
B. Short half-life guarantees greater efficacy
C. Short half-life prevents hepatic metabolism
D. Short half-life eliminates the possibility of adverse effects
Correct Answer: A
Rationale: Drugs with short half-lives are eliminated relatively rapidly and may require more
frequent dosing to maintain therapeutic concentrations. Half-life does not by itself determine
efficacy or eliminate adverse effects.
Question 7
A patient experiences adverse effects shortly after beginning a psychotropic medication, despite
receiving the recommended dose. Which pharmacokinetic factor can contribute to unusually high
exposure?
A. Genetic variation in drug-metabolizing enzymes
B. Therapeutic adherence
, C. Placebo response
D. Receptor downregulation alone
Correct Answer: A
Rationale: Pharmacogenetic differences can cause some individuals to metabolize medications
more slowly or rapidly than expected, altering exposure. Placebo response and receptor
regulation involve pharmacodynamic rather than primary pharmacokinetic mechanisms.
Question 8
Which term describes the process by which a medication produces its biologic effect after
binding to a receptor?
A. Pharmacokinetics
B. Pharmacodynamics
C. Bioavailability
D. Clearance
Correct Answer: B
Rationale: Pharmacodynamics concerns what a drug does to the body, including receptor
interactions and downstream physiologic effects. Pharmacokinetics describes what the body does
to the drug through absorption, distribution, metabolism, and elimination.
Question 9
A patient stops taking a medication abruptly after long-term use and develops symptoms
associated with physiologic adaptation. Which concept best explains this phenomenon?
A. Drug tolerance
B. Physical dependence
C. Therapeutic index
D. First-pass metabolism
Correct Answer: B
Rationale: Physical dependence occurs when neuroadaptation produces withdrawal symptoms
after dose reduction or discontinuation. Tolerance refers to reduced response requiring increased
exposure, whereas first-pass metabolism concerns oral drug disposition.
Question 10
A patient reports that the same dose of a medication has become progressively less effective over
several months. Which phenomenon is most consistent with this report?
A. Tolerance
B. Bioavailability
